Marc GuntherHow Yale researchers helped create the ketamine industry — and their own psychedelics startup.The clinical trial that set the stage for today’s fast-growing ketamine industry runs just three pages long and involved only eight…·7 min read·Sep 21, 2023----
Marc GuntherThe psychedelics movement has come a long way in a hurryA report from MAPS Psychedelic Science 2023 conference.·7 min read·Jun 27, 2023--2--2
Marc GuntherWhy I invested in TactogenMDMA is a wonderful medicine. This startup company wants to make it even better.·6 min read·May 2, 2023--1--1
Marc GuntherPsychedelics startup Gilgamesh has no interest in psilocybin or LSDIt’s developing new compounds and attracting investors·8 min read·Mar 9, 2023--2--2
Marc GuntherA psychedelics startup has a big vision. Investors aren’t buying it.Awakn Life Science’s ketamine therapy for alcohol use disorder is promising. Will it be profitable?·7 min read·Jan 20, 2023--1--1
Marc GuntherRoland Griffiths, and his legacyA Johns Hopkins professor and leading researcher of psychedelics faces his death and invites others to carry on his work.·7 min read·Jan 12, 2023--1--1
Marc GuntherAt Horizons 2022, a cloudy outlook for psychedelicsScientific research and drug reform are moving forward. The business of psychedelic medicines? Not so much.·5 min read·Oct 17, 2022--1--1
Marc GuntherChurches are providing psychedelics to their followers. Is that legal?Some lawyers say plant-medicine churches are exercising their freedom of religion. Others advise caution. It’s complicated.·9 min read·Oct 4, 2022----
Marc GuntherBeyond Michael Pollan: Where to learn more about psychedelics.A guide for the curious to the best books, writers, filmmakers and talkers about psychedelics·4 min read·Sep 19, 2022--2--2
Marc GuntherCody Swift’s big bets are paying offHis philanthropy is helping to drive the psychedelic renaissance·8 min read·Sep 12, 2022----